Company name Able: Tx * Website: able-tx.com * CEO name: Nir Betser

CATEGORY: Biotech/Pharma SESSION: Restoring Vision: Where Biology Meets Engineering. You may delete the section instructions, leaving only the bolded bullet title Answers below should not exceed 60 words per question: Executive Summary / Investment Rationale Able Tx is on a mission to restore and preserve vision without the need for intraocular injections, enabling at-home, selfadministered therapies. These treatments are designed to become first-line care for vision-threatening diseases and support a future of personalized, preventive treatment for millions of patients. Targeting a large, underserved retinal market with no approved topical options, the company has treated more than 90 patients across three clinical programs with strong safety and efficacy results. Backed by investors and grants, with experienced leadership and in-house GMP capabilities. Raising Series A. Core Technology Smatrix is a proprietary, degradable, drug-eluting matrix enabling sustained drug delivery via the uveoscleral route. It combines injection-level efficacy with topical convenience, offering high bioavailability, reversibility, and compatibility with multiple APIs. The platform overcomes ocular barriers via uveoscleral route and enables controlled, patient-friendly treatment. Six patent families, with additional patents in drafting. Product Profile / Pipeline AMX300 is a lead candidate in Phase 2a for DME (Diabetic Macular Edema), with early data form 10+ patients showing meaningful edema reduction and visual acuity improvement, including a clear on/off pharmacological effect. The study is an open-label, multicenter trial with QD/BID dosing over 6–12 weeks .Additional programs include AMX500 (corneal diseases, entering clinic H1 2026) and AMX800 (topical anti-VEGF for AMD, first patient expected Q4 2026). Business Strategy For its lead asset, AMX300, Able Tx plans to enter the market by initially targeting anti-VEGF non-responders (~40% of treated patients). Following clinical validation, the strategy expands toward earlier-line use, positioning AMX300 as a firstline, non-invasive alternative for a broader untreated DME population, shifting care to proactive, at-home therapy. What’s Next? Key next steps include advancing AMX300 Phase 2 and preparing for Phase 3, initiating AMX500 and AMX800 clinical studies, and expanding clinical sites globally. The company plans to pursue regulatory interactions, scale manufacturing, and secure funding and partnerships to support pipeline advancement and commercialization